PMID- 27405296
OWN - NLM
STAT- MEDLINE
DCOM- 20170324
LR  - 20181113
IS  - 1476-511X (Electronic)
IS  - 1476-511X (Linking)
VI  - 15
IP  - 1
DP  - 2016 Jul 12
TI  - Effects of extended-release niacin/laropiprant on correlations between 
      apolipoprotein B, LDL-cholesterol and non-HDL-cholesterol in patients with type 2 
      diabetes.
PG  - 116
LID - 10.1186/s12944-016-0282-8 [doi]
LID - 116
AB  - BACKGROUND: LDL-C, non-HDL-C and ApoB levels are inter-correlated and all predict 
      risk of atherosclerotic cardiovascular disease (ASCVD) in patients with type 2 
      diabetes mellitus (T2DM) and/or high TG. These levels are lowered by 
      extended-release niacin (ERN), and changes in the ratios of these levels may 
      affect ASCVD risk. This analysis examined the effects of extended-release 
      niacin/laropiprant (ERN/LRPT) on the relationships between apoB:LDL-C and 
      apoB:non-HDL-C in patients with T2DM. METHODS: T2DM patients (n = 796) had LDL-C 
      >/=1.55 and <2.97 mmol/L and TG <5.65 mmol/L following a 4-week, lipid-modifying 
      run-in (~78 % taking statins). ApoB:LDL-C and apoB:non-HDL-C correlations were 
      assessed after randomized (4:3), double-blind ERN/LRPT or placebo for 12 weeks. 
      Pearson correlation coefficients between apoB:LDL-C and apoB:non-HDL-C were 
      computed and simple linear regression models were fitted for apoB:LDL-C and 
      apoB:non-HDL-C at baseline and Week 12, and the correlations between measured 
      apoB and measured vs predicted values of LDL-C and non-HDL-C were studied. 
      RESULTS: LDL-C and especially non-HDL-C were well correlated with apoB at 
      baseline, and treatment with ERN/LRPT increased these correlations, especially 
      between LDL-C and apoB. Despite the tighter correlations, many patients who 
      achieved non-HDL-C goal, and especially LDL-C goal, remained above apoB goal. 
      There was a trend towards greater increases in these correlations in the higher 
      TG subgroup, non-significant possibly due to the small number of subjects. 
      CONCLUSIONS: ERN/LRPT treatment increased association of apoB with LDL-C and 
      non-HDL-C in patients with T2DM. Lowering LDL-C, non-HDL-C and apoB with niacin 
      has the potential to reduce coronary risk in patients with T2DM.
FAU - Brinton, Eliot A
AU  - Brinton EA
AD  - Division of Atherometabolic Research, Utah Foundation for Biomedical Research, 
      420 Chipeta Way, Room 1160, Salt Lake City, UT, 84108, USA. 
      eliot.brinton@utah.edu.
FAU - Triscari, Joseph
AU  - Triscari J
AD  - Merck & Co., Inc., Kenilworth, NJ, USA.
FAU - Brudi, Philippe
AU  - Brudi P
AD  - Merck & Co., Inc., Kenilworth, NJ, USA.
FAU - Chen, Erluo
AU  - Chen E
AD  - Merck & Co., Inc., Kenilworth, NJ, USA.
FAU - Johnson-Levonas, Amy O
AU  - Johnson-Levonas AO
AD  - Merck & Co., Inc., Kenilworth, NJ, USA.
FAU - Sisk, Christine McCrary
AU  - Sisk CM
AD  - Merck & Co., Inc., Kenilworth, NJ, USA.
FAU - Ruck, Rae Ann
AU  - Ruck RA
AD  - Merck & Co., Inc., Kenilworth, NJ, USA.
FAU - MacLean, Alexandra A
AU  - MacLean AA
AD  - Merck & Co., Inc., Kenilworth, NJ, USA.
FAU - Maccubbin, Darbie
AU  - Maccubbin D
AD  - Merck & Co., Inc., Kenilworth, NJ, USA.
FAU - Mitchel, Yale B
AU  - Mitchel YB
AD  - Merck & Co., Inc., Kenilworth, NJ, USA.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20160712
PL  - England
TA  - Lipids Health Dis
JT  - Lipids in health and disease
JID - 101147696
RN  - 0 (APOB protein, human)
RN  - 0 (Apolipoprotein B-100)
RN  - 0 (Blood Glucose)
RN  - 0 (Cholesterol, HDL)
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Hypolipidemic Agents)
RN  - 0 (Indoles)
RN  - 0 (Insulin)
RN  - 0 (MK-0524)
RN  - 0 (Triglycerides)
RN  - 2679MF687A (Niacin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Apolipoprotein B-100/*blood
MH  - Blood Glucose/metabolism
MH  - Cholesterol, HDL/blood
MH  - Cholesterol, LDL/*blood
MH  - Delayed-Action Preparations/*therapeutic use
MH  - Diabetes Mellitus, Type 2/blood/drug therapy/physiopathology
MH  - Double-Blind Method
MH  - Fasting
MH  - Female
MH  - Humans
MH  - Hyperlipidemias/blood/*drug therapy/physiopathology
MH  - Hypoglycemic Agents/therapeutic use
MH  - Hypolipidemic Agents/*therapeutic use
MH  - Indoles/*therapeutic use
MH  - Insulin/blood
MH  - Male
MH  - Middle Aged
MH  - Niacin/*therapeutic use
MH  - Triglycerides/blood
PMC - PMC4942972
OTO - NOTNLM
OT  - ApoB
OT  - Extended-release niacin/laropiprant
OT  - LDL-C and non-HDL-C
OT  - Type 2 diabetes mellitus
EDAT- 2016/07/14 06:00
MHDA- 2017/03/25 06:00
PMCR- 2016/07/12
CRDT- 2016/07/14 06:00
PHST- 2016/05/03 00:00 [received]
PHST- 2016/06/23 00:00 [accepted]
PHST- 2016/07/14 06:00 [entrez]
PHST- 2016/07/14 06:00 [pubmed]
PHST- 2017/03/25 06:00 [medline]
PHST- 2016/07/12 00:00 [pmc-release]
AID - 10.1186/s12944-016-0282-8 [pii]
AID - 282 [pii]
AID - 10.1186/s12944-016-0282-8 [doi]
PST - epublish
SO  - Lipids Health Dis. 2016 Jul 12;15(1):116. doi: 10.1186/s12944-016-0282-8.